Newborn screening for ALD saves lives by enabling early treatment of adrenal disease and cerebral ALD 💙. However, challenges can arise when screening identifies a variant of uncertain significance (VUS) in the ABCD1 gene. This means that parents don’t know if their child will develop the disease. The result is years of anxiety and repeated blood tests and MRI scans under anesthesia every six months, often for children who will never exhibit symptoms in childhood.
We asked ourselves: “Can we do better?”
Through the Grey Zone Project, we developed a risk assessment framework that combines genetic data and biochemical measurements (LPC(26:0) levels).[Click to read more ▼]
After analyzing 1,627 healthy controls and 196 ALD patients with detailed clinical follow-up, we established evidence-based thresholds that classify variants into three clear categories: ‘no ALD’, ‘lower risk of childhood disease’ and ‘at risk of childhood disease’.
We applied this framework to 108 samples representing 51 unique VUSs.
🟢 26 VUSs were reclassified as ‘no ALD’.
🟡 15 VUSs were identified as ‘lower risk for childhood disease’.
🔴 10 VUSs were identified as ‘at risk of childhood disease’.
The Grey Zone Project aims to improve diagnostics. It’s also about providing families with clarity during critical moments, minimizing unnecessary medical interventions, and ensuring that children who require monitoring receive it.
All reclassification data feed back into the ABCD1 Variant Registry and ‘no ALD’ variants will be reclassified as ‘benign, confirmed by normal LPC(26:0) levels’.